116 related articles for article (PubMed ID: 23482748)
41. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
42. Effects of the HIF1 inhibitor, echinomycin, on growth and NOTCH signalling in leukaemia cells.
Yonekura S; Itoh M; Okuhashi Y; Takahashi Y; Ono A; Nara N; Tohda S
Anticancer Res; 2013 Aug; 33(8):3099-103. PubMed ID: 23898065
[TBL] [Abstract][Full Text] [Related]
43. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
44. Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis.
Huo Y; Iadevaia V; Yao Z; Kelly I; Cosulich S; Guichard S; Foster LJ; Proud CG
Biochem J; 2012 May; 444(1):141-51. PubMed ID: 22428559
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic Suppression of mTOR (Mammalian Target of Rapamycin) Signaling Prevents and Reverses Salt-Induced Hypertension and Kidney Injury in Dahl Salt-Sensitive Rats.
Kumar V; Evans LC; Kurth T; Yang C; Wollner C; Nasci V; Zheleznova NN; Bukowy J; Dayton A; Cowley AW
Hypertension; 2019 Mar; 73(3):630-639. PubMed ID: 30595123
[TBL] [Abstract][Full Text] [Related]
46. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
47. Ro 31-6045, the inactive analogue of the protein kinase C inhibitor Ro 31-8220, blocks in vivo activation of p70(s6k)/p85(s6k): implications for the analysis of S6K signalling.
Marmy-Conus N; Hannan KM; Pearson RB
FEBS Lett; 2002 May; 519(1-3):135-40. PubMed ID: 12023032
[TBL] [Abstract][Full Text] [Related]
48. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.
Dutton A; Reynolds GM; Dawson CW; Young LS; Murray PG
J Pathol; 2005 Mar; 205(4):498-506. PubMed ID: 15714459
[TBL] [Abstract][Full Text] [Related]
49. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
Bishop JD; Nien WL; Dauphinee SM; Too CK
J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564
[TBL] [Abstract][Full Text] [Related]
50. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
51. Distinct perturbation of the translatome by the antidiabetic drug metformin.
Larsson O; Morita M; Topisirovic I; Alain T; Blouin MJ; Pollak M; Sonenberg N
Proc Natl Acad Sci U S A; 2012 Jun; 109(23):8977-82. PubMed ID: 22611195
[TBL] [Abstract][Full Text] [Related]
52. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Li J; Xue L; Hao H; Han Y; Yang J; Luo J
Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
[TBL] [Abstract][Full Text] [Related]
53. Administration of dexamethasone disrupts endometrial receptivity by alteration of expression of miRNA 223, 200a, LIF, Muc1, SGK1, and ENaC via the ERK1/2-mTOR pathway.
Shariati MBH; Niknafs B; Seghinsara AM; Shokrzadeh N; Alivand MR
J Cell Physiol; 2019 Nov; 234(11):19629-19639. PubMed ID: 30993706
[TBL] [Abstract][Full Text] [Related]
54. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
55. Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.
Waetzig R; Matthes M; Leister J; Penkivech G; Heise T; Corbacioglu S; Sommer G
Int J Med Sci; 2021; 18(1):137-149. PubMed ID: 33390782
[TBL] [Abstract][Full Text] [Related]
56. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
57. mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy.
Seo SU; Woo SM; Lee HS; Kim SH; Min KJ; Kwon TK
Oncogene; 2018 Sep; 37(38):5205-5220. PubMed ID: 29849119
[TBL] [Abstract][Full Text] [Related]
58. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism.
Liu LL; Long ZJ; Wang LX; Zheng FM; Fang ZG; Yan M; Xu DF; Chen JJ; Wang SW; Lin DJ; Liu Q
Mol Cancer Res; 2013 Nov; 11(11):1326-36. PubMed ID: 24008673
[TBL] [Abstract][Full Text] [Related]
60. Role of the mTOR signalling pathway in salivary gland development.
Sakai M; Fukumoto M; Ikai K; Ono Minagi H; Inagaki S; Kogo M; Sakai T
FEBS J; 2019 Sep; 286(18):3701-3717. PubMed ID: 31120172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
